Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Casper Strandholdt"'
Autor:
Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen, Eigil Kjeldsen, Katrine Fladeland Iversen, Elena Manuela Teodorescu, Marveh Dokhi, Eva Kurt, Casper Strandholdt, Mette Klarskov Andersen, Annette Juul Vangsted
Publikováno v:
PLoS ONE, Vol 16, Iss 10, p e0258487 (2021)
Most patients cannot be included in randomized clinical trials. We report real-world outcomes of all Danish patients with multiple myeloma (MM) treated with daratumumab-based regimens until 1 January 2019.MethodsInformation of 635 patients treated wi
Externí odkaz:
https://doaj.org/article/3a1957b6a5774014bba30b82888f0eeb
Autor:
Annette Juul Vangsted, Manuela Teodorescu, Birgitte Preiss, Mette Bøegh Levring, Jonathan Thorsen, Agoston Gyula Szabo, Eva Kurt, Lise Mette Rahbek Gjerdrum, Carsten Helleberg, Marie Fredslund Breinholt, Katrine Nielsen, Marveh Dokhi, Katrine Fladeland Iversen, Mette K. Andersen, Emil Hermansen, Eigil Kjeldsen, Søren Bønløkke, Casper Strandholdt
Publikováno v:
Szabo, A G, Thorsen, J, Iversen, K F, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Gjerdrum, L M R, Bønløkke, S T, Nielsen, K, Kjeldsen, E, Teodorescu, E M, Dokhi, M, Kurt, E, Strandholdt, C N, Andersen, M K & Vangsted, A J 2022, ' The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy ', American Journal of Hematology, vol. 97, no. 3, pp. E117-E120 . https://doi.org/10.1002/ajh.26449
Szabo, A G, Thorsen, J, Iversen, K F, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Gjerdrum, L M R, Bønløkke, S, Nielsen, K, Kjeldsen, E, Teodorescu, M, Dokhi, M, Kurt, E, Strandholdt, C N, Andersen, M K & Vangsted, A J 2021, ' The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy ', Blood, vol. 138, no. Suppl. 1, 3779 . https://doi.org/10.1182/blood-2021-152070
Szabo, A G, Thorsen, J, Iversen, K F, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Gjerdrum, L M R, Bønløkke, S, Nielsen, K, Kjeldsen, E, Teodorescu, M, Dokhi, M, Kurt, E, Strandholdt, C N, Andersen, M K & Vangsted, A J 2021, ' The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy ', Blood, vol. 138, no. Suppl. 1, 3779 . https://doi.org/10.1182/blood-2021-152070
Daratumumab is an integral part of the treatment of multiple myeloma (MM) but its real-world efficacy has only been described in small cohorts. MAMMOTH is the only large multi-center study that reported the outcomes of CD38-refractory MM. The present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::297707d8db084b25ae8fb54726820d26
https://portal.findresearcher.sdu.dk/da/publications/035148e8-81ab-4df0-9c3e-3f92d4c8d59e
https://portal.findresearcher.sdu.dk/da/publications/035148e8-81ab-4df0-9c3e-3f92d4c8d59e
Autor:
Marie Fredslund Breinholt, Carsten Helleberg, Agoston Gyula Szabo, Mette Bøegh Levring, Katrine Nielsen, Eigil Kjeldsen, Søren Bønløkke, Katrine Fladeland Iversen, Mette K. Andersen, Birgitte Preiss, Elena Manuela Teodorescu, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Henrik Gregersen, Eva Kurt, Casper Strandholdt, Tobias Wirenfeldt Klausen, Annette Juul Vangsted, Karen Louise Højholt
Publikováno v:
Højholt, K L, Gregersen, H, Szabo, A G, Klausen, T W, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Rahbek Gjerdrum, L M, Bønløkke, S T, Nielsen, K, Kjeldsen, E, Iversen, K F, Teodorescu, E M, Kurt, E, Strandholdt, C, Andersen, M K & Vangsted, A J 2021, ' Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients ', Hematological Oncology, vol. 39, no. 4, pp. 521-528 . https://doi.org/10.1002/hon.2906
Real world evidence is important since most patients cannot be included in randomized clinical trials (RCTs). In a nationwide, cohort of relapsed/refractory multiple myeloma patients treated with daratumumab (N = 635), we retrospective studied patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61024888296e62b7a6177aeb85a53828
https://portal.findresearcher.sdu.dk/da/publications/3205a743-e998-4521-9f10-c9df06ddd93b
https://portal.findresearcher.sdu.dk/da/publications/3205a743-e998-4521-9f10-c9df06ddd93b
Autor:
Simon Bertram Flaeng, Elena Manuela Teodorescu, Annette Juul Vangsted, Dorrit Krustrup, Simon Bo Pedersen, Torben Plesner, Agoston Gyula Szabo, Katrine Fladeland Iversen, Casper Strandholdt, Jonathan Thorsen, Maja Ølholm Vase, Charlotte Toftmann Hansen, Mikael Frederiksen, Ulf Christian Frølund
Publikováno v:
Szabo, A G, Thorsen, J, Iversen, K F, Hansen, C T, Teodorescu, E M, Pedersen, S B, Flæng, S B, Strandholdt, C, Frederiksen, M, Vase, M, Frølund, U C, Krustrup, D, Plesner, T & Vangsted, A J 2020, ' Clinically-suspected cast nephropathy : A retrospective, national, real-world study ', American Journal of Hematology, vol. 95, no. 11, pp. 1352-1360 . https://doi.org/10.1002/ajh.25959
Szabo, A G, Thorsen, J, Iversen, K F, Hansen, C T, Teodorescu, E M, Pedersen, S B, Flaeng, S B, Strandholdt, C, Frederiksen, M, Vase, M Ø, Frølund, U C, Krustrup, D, Plesner, T & Vangsted, A J 2020, ' Clinically-suspected cast nephropathy : A retrospective, national, real-world study ', American Journal of Hematology, vol. 95, no. 11, pp. 1352-1360 . https://doi.org/10.1002/ajh.25959
Szabo, A G, Thorsen, J, Iversen, K F, Hansen, C T, Teodorescu, E M, Pedersen, S B, Flaeng, S B, Strandholdt, C, Frederiksen, M, Vase, M Ø, Frølund, U C, Krustrup, D, Plesner, T & Vangsted, A J 2020, ' Clinically-suspected cast nephropathy : A retrospective, national, real-world study ', American Journal of Hematology, vol. 95, no. 11, pp. 1352-1360 . https://doi.org/10.1002/ajh.25959
Presentation with severe acute kidney injury due to cast nephropathy (CN) is a medical emergency in multiple myeloma (MM), with high risk of dialysis-dependent renal failure and death. Accrual of patients with CN into interventional studies is diffic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::195ff815d40ea19694f7732181966d12
https://findresearcher.sdu.dk:8443/ws/files/173188899/ajh.25959.pdf
https://findresearcher.sdu.dk:8443/ws/files/173188899/ajh.25959.pdf
Autor:
Katrine Nielsen, Katrine Fladeland Iversen, Annette Juul Vangsted, Marie Fredslund Breinholt, Birgitte Preiss, Mette Bøegh Levring, Mette K. Andersen, Carsten Helleberg, Eva Kurt, Lise Mette Rahbek Gjerdrum, Søren Bønløkke, Marveh Dokhi, Eigil Kjeldsen, Tobias Wirenfeldt Klausen, Casper Strandholdt, Elena Manuela Teodorescu, Emil Hermansen, Agoston Gyula Szabo
Publikováno v:
Szabo, A G, Klausen, T W, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Gjerdrum, L M R, Bønløkke, S T, Nielsen, K, Kjeldsen, E, Iversen, K F, Teodorescu, E M, Dokhi, M, Kurt, E, Strandholdt, C, Andersen, M K & Vangsted, A J 2021, ' The real-world outcomes of multiple myeloma patients treated with daratumumab ', PLoS ONE, vol. 16, no. 10, e0258487 . https://doi.org/10.1371/journal.pone.0258487
PLoS ONE, Vol 16, Iss 10, p e0258487 (2021)
Szabo, A G, Klausen, T W, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Gjerdrum, L M R, Bønløkke, S T, Nielsen, K, Kjeldsen, E, Iversen, K F, Teodorescu, E M, Dokhi, M, Kurt, E, Strandholdt, C, Andersen, M K & Vangsted, A J 2021, ' The real-world outcomes of multiple myeloma patients treated with daratumumab ', Plos One, vol. 16, no. 10 October, e0258487, pp. 1-11 . https://doi.org/10.1371/journal.pone.0258487
PLoS ONE
Szabo, A G, Klausen, T W, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Gjerdrum, L M R, Bønløkke, S T, Nielsen, K, Kjeldsen, E, Iversen, K F, Teodorescu, E M, Dokhi, M, Kurt, E, Strandholdt, C, Andersen, M K & Vangsted, A J 2021, ' The real-world outcomes of multiple myeloma patients treated with daratumumab ', PLOS ONE, vol. 16, no. 10, e0258487 . https://doi.org/10.1371/journal.pone.0258487
PLoS ONE, Vol 16, Iss 10, p e0258487 (2021)
Szabo, A G, Klausen, T W, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Gjerdrum, L M R, Bønløkke, S T, Nielsen, K, Kjeldsen, E, Iversen, K F, Teodorescu, E M, Dokhi, M, Kurt, E, Strandholdt, C, Andersen, M K & Vangsted, A J 2021, ' The real-world outcomes of multiple myeloma patients treated with daratumumab ', Plos One, vol. 16, no. 10 October, e0258487, pp. 1-11 . https://doi.org/10.1371/journal.pone.0258487
PLoS ONE
Szabo, A G, Klausen, T W, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Gjerdrum, L M R, Bønløkke, S T, Nielsen, K, Kjeldsen, E, Iversen, K F, Teodorescu, E M, Dokhi, M, Kurt, E, Strandholdt, C, Andersen, M K & Vangsted, A J 2021, ' The real-world outcomes of multiple myeloma patients treated with daratumumab ', PLOS ONE, vol. 16, no. 10, e0258487 . https://doi.org/10.1371/journal.pone.0258487
Most patients cannot be included in randomized clinical trials. We report real-world outcomes of all Danish patients with multiple myeloma (MM) treated with daratumumab-based regimens until 1 January 2019. Methods Information of 635 patients treated